scholarly article | Q13442814 |
P50 | author | Jenny Morton | Q42857576 |
P2093 | author name string | David Hernández-Espinosa | |
P433 | issue | 6 | |
P921 | main subject | Huntington's disease | Q190564 |
P304 | page(s) | 669-679 | |
P577 | publication date | 2006-04-18 | |
P1433 | published in | Brain Research Bulletin | Q4955784 |
P1476 | title | Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation | |
P478 | volume | 69 |
Q37798463 | Bringing natural products into the fold - exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases |
Q30462195 | Calcineurin activity in children with Mental handicap |
Q40020558 | Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells |
Q43071425 | Cyclosporine A attenuates 3-nitropropionic acid-induced Huntington-like symptoms in rats: possible nitric oxide mechanism |
Q34605764 | Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli |
Q45301226 | Mutant huntingtin alters Tau phosphorylation and subcellular distribution |
Q37930190 | Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. |
Q34017941 | Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice |
Q38957994 | Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease. |
Q36999830 | Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body |